Business Novartis' patent on diabetes drug Vildagliptin expires tomorrow, prices to fall by 60% Updated : December 09, 2019 02:55 PM IST Vildagliptin is a part of a class of diabetes medications called dipeptidyl peptidase IV or DPP4 inhibitors. Novartis’ patent on Vildagliptin is expiring on December 9, 2019, and companies can sell its generic version from tomorrow. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.